Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Some preclinical in vivo studies and limited human data suggest a possible increased risk of bladder cancer with pioglitazone therapy. This is an interim report of an ongoing cohort study examining the association between pioglitazone therapy and the risk of bladder cancer in patients with diabetes. RESEARCH DESIGN AND METHODS: This study includes 193,099 patients in the Kaiser Permanente Northern California diabetes registry who were ≥40 years of age between 1997 and 2002. Those with prior bladder cancer were excluded. Ever use of each diabetes medication (defined as two or more prescriptions within 6 months) was treated as a time-dependent variable. Cox regression–generated hazard ratios (HRs) compared pioglitazone use with nonpioglitazone use adjusted for age, sex, race/ethnicity, diabetes medications, A1C, heart failure, household income, renal function, other bladder conditions, and smoking. RESULTS: The group treated with pioglitazone comprised 30,173 patients. There were 90 cases of bladder cancer among pioglitazone users and 791 cases of bladder cancer among nonpioglitazone users. Overall, ever use of pioglitazone was not associated with risk of bladder cancer (HR 1.2 [95% CI 0.9–1.5]), with similar results in men and women (test for interaction P = 0.8). However, in the a priori category of >24 months of therapy, there was an increased risk (1.4 [1.03–2.0]). Ninety-five percent of cancers diagnosed among pioglitazone users were detected at early stage. CONCLUSIONS: In this cohort of patients with diabetes, short-term use of pioglitazone was not associated with an increased incidence of bladder cancer, but use for more than 2 years was weakly associated with increased risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Observational research conducted in 2011 and 2012 suggested that pioglitazone may increase the risk of bladder cancer.46,47”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [46]
The cited source says what the claim attributes to it.
In the citing paper
“Of note, some data suggest an association between the use of pioglitazone and an increased risk of bladder cancer (191).”
From Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline (2012) · cites this paper as [191]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · Diabetes Care · doi:10.2337/dc10-0666 · Cited by 2,366
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
Currie, C. J., Poole, C. D., & Gale, E. A. M. (2009) · Diabetologia · doi:10.1007/s00125-009-1440-6 · Cited by 1,124 · cited 1×
“Some research suggests that metformin use is associated with a reduced risk for various cancers (23,24); others have suggested that insulin use might increase the risk of cancer (24,25).”
BackgroundDiabetes and Cancer: A Consensus Report
Giovannucci, E., Harlan, D. M., Archer, M. C., Bergenstal, R. M., Gapstur, S. M., Habel, L. A., Pollak, M., Regensteiner, J. G., & Yee, D. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20078 · Cited by 1,055
Elstner, E., Müller, C., Koshizuka, K., Williamson, E. A., Park, D., Asou, H., Shintaku, P., Said, J. W., Heber, D., & Koeffler, H. P. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8806 · Cited by 805
Tontonoz, P., Singer, S., Forman, B. M., Sarraf, P., Fletcher, J. A., Fletcher, C. D. M., Brun, R. P., Mueller, E., Altiok, S., Oppenheim, H., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.1.237 · Cited by 653
Kubota, T., Koshizuka, K., Williamson, E. A., Asou, H., SAID, J. W., Holden, S. A., Miyoshi, I., & Koeffler, H. P. (1998) · PubMed · Cited by 589
Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes
Govindarajan, R., Ratnasinghe, L., Simmons, D. L., Siegel, E. R., Midathada, M. V., Kim, L., Kim, P. J., Owens, R. J., & Lang, N. P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.2777 · Cited by 336
Cited by
Items 101–200 of 711
Pelham, C. J., Ketsawatsomkron, P., Groh, S., Grobe, J. L., de Lange, W. J., Ibeawuchi, S.-R. C., Keen, H. L., Weatherford, E. T., Faraci, F. M., & Sigmund, C. D. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.08.011 · Cited by 99
Mata‐Cases, M., Franch‐Nadal, J., Real, J., & Mauricio, D. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-012463 · Cited by 99
History of current non-insulin medications for diabetes mellitus
Quianzon, C. C. L., & Cheikh, I. E. (2012) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.3402/jchimp.v2i3.19081 · Cited by 96
Gastrointestinal Complications of Diabetes
Boland, B. S., Edelman, S. V., & Wolosin, J. D. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.07.006 · Cited by 96
Getting ‘Smad’ about obesity and diabetes
Tan, C. K., Chong, H. C., Tan, E. H. P., & Tan, N. S. (2012) · Nutrition & Diabetes · doi:10.1038/nutd.2012.1 · Cited by 95
Zhu, Z., Wang, X., Shen, Z., Lu, Y., Zhong, S., & Xu, C. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-310 · Cited by 93
Zhang, F., Kong, D., Lu, Y., & Zheng, S. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1046-x · Cited by 92
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
Vella, V., Nicolosi, M. L., Giuliano, S., Bellomo, M., Belfiore, A., & Malaguarnera, R. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00031 · Cited by 91
Halstead, A. M., Kapadia, C. D., Bolzenius, J. K., Chu, C. E., Schriefer, A. E., Wartman, L. D., Bowman, G. R., & Arora, V. K. (2017) · eLife · doi:10.7554/elife.30862 · Cited by 90
Idris, I., Warren, G., & Donnelly, R. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.1938 · Cited by 88
Latest insights into the risk of cancer in diabetes
Noto, H., Goto, A., Tsujimoto, T., Osame, K., & Noda, M. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12068 · Cited by 88
Kohro, T., Yamazaki, T., Sato, H., Harada, K., Ohe, K., Komuro, I., & Nagai, R. (2013) · International Heart Journal · doi:10.1536/ihj.54.93 · Cited by 88
Kasuga, M., Ueki, K., Tajima, N., Noda, M., Ohashi, K., Noto, H., Goto, A., Ogawa, W., Sakai, R., Tsugane, S., et al. (2013) · Cancer Science · doi:10.1111/cas.12203 · Cited by 88
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
Filipova, E., Uzunova, K., Kalinov, K., & Vekov, T. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0273-4 · Cited by 87
Pioglitazone and bladder cancer: a propensity score matched cohort study
Wei, L., MacDonald, T. M., & Mackenzie, I. S. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04325.x · Cited by 86
Bailey, T. S. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2013.06.009 · Cited by 84
The Epidemiology and Molecular Mechanisms Linking Obesity, Diabetes, and Cancer
Ferguson, R. D., Gallagher, E. J., Scheinman, E. J., Damouni, R., & LeRoith, D. (2013) · Vitamins and hormones · doi:10.1016/b978-0-12-416673-8.00010-1 · Cited by 83
Zeng, X., Wang, Y., Cantley, J., Iseli, T. J., Molero, J. C., Hegarty, B. D., Kraegen, E. W., Yang, Y., & Ye, J.-M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042115 · Cited by 83
Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies
Tomic, D., Kemp, W. W., & Roberts, S. K. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001235 · Cited by 83
Importance of Beta Cell Function for the Treatment of Type 2 Diabetes
Saisho, Y. (2014) · Journal of Clinical Medicine · doi:10.3390/jcm3030923 · Cited by 82
Zhan, Y., Lin, J., Liu, Y., Chen, M., Chen, X., Zhuang, C., Liu, L., Xu, W., Chen, Z., He, A., et al. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0354-7 · Cited by 80
Zhang, L., Chen, Q., Li, L., Kwong, J. S. W., Jia, P., Zhao, P., Wang, W., Zhou, X., Zhang, M., & Sun, X. (2016) · Scientific Reports · doi:10.1038/srep32649 · Cited by 80
Francisco, V., Sanz, M. J., Real, J. T., Marques, P., Capuozzo, M., Ait Eldjoudi, D., & Gualillo, O. (2022) · Biology · doi:10.3390/biology11081237 · Cited by 79
Saroglitazar for the treatment of dyslipidemia in diabetic patients
Joshi, S. R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1009894 · Cited by 79
Effects of SGLT2 inhibitors on cardiovascular outcomes
Foote, C., Perkovic, V., & Neal, B. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441190 · Cited by 77
Hsiao, F., Hsieh, P.-H., Huang, W.-F., Tsai, Y., & Gau, C. (2013) · Drug Safety · doi:10.1007/s40264-013-0080-4 · Cited by 77
Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?
Consoli, A., & Formoso, G. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12101 · Cited by 76
Examining the safety of PPAR agonists – current trends and future prospects
Bortolini, M., Wright, M. B., Bopst, M., & Balas, B. (2013) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2013.741585 · Cited by 75
Quan, Q., Wang, J., Li, X., & Wang, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059155 · Cited by 75
Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
Hassen, G., Singh, A., Belete, G., Jain, N., la Hoz, I. D., Camacho-Leon, G., Dargie, N. K., Carrera, K. G., Alemu, T., Jhaveri, S., et al. (2022) · Cureus · doi:10.7759/cureus.25495 · Cited by 75
Diabetes Mellitus and Risk of Bladder Cancer: A Meta-Analysis of Cohort Studies
Zhu, Z., Zhang, X., Shen, Z., Zhong, S., Wang, X., Lu, Y., & Chen, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056662 · Cited by 75
The current role of thiazolidinediones in diabetes management
Rizos, C. V., Kei, A. A., & Elisaf, M. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1737-4 · Cited by 75
Effect of anti-diabetic drugs on bone metabolism: Evidence from preclinical and clinical studies
Adil, M., Khan, R. A., Kalam, A., Venkata, S. K., Kandhare, A. D., Ghosh, P., & Sharma, M. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.05.008 · Cited by 75
Controversies in the Diagnosis and Management of NAFLD and NASH.
Rinella, M. E., Loomba, R. S., Caldwell, S. H., Kowdley, K. V., Charlton, M., Tetri, B. A., & Harrison, S. A. (2014) · PubMed · Cited by 74
Mal, S., Dwivedi, A. R., Kumar, V., Kumar, N., Kumar, B., & Kumar, V. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200716113136 · Cited by 73
The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes
Amod, A. (2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872276 · Cited by 73
PPAR-γ Partial Agonists in Disease-Fate Decision with Special Reference to Cancer
Ballav, S., Biswas, B., Sahu, V. K., Ranjan, A., & Basu, S. (2022) · Cells · doi:10.3390/cells11203215 · Cited by 72
Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2035 · Cited by 71
Incidence of Bladder Cancer in Patients With Type 2 Diabetes Treated With Metformin or Sulfonylureas
Mamtani, R., Pfanzelter, N., Haynes, K., Finkelman, B. S., Wang, X., Keefe, S. M., Haas, N. B., Vaughn, D. J., & Lewis, J. D. (2014) · Diabetes Care · doi:10.2337/dc13-1489 · Cited by 71
Self-citationSingh, S., & Bhansali, A. (2016) · BMC Dermatology · doi:10.1186/s12895-016-0049-y · Cited by 71
Korhonen, P. A., Heintjes, E. M., Williams, R., Hoti, F. J., Christopher, S., Majak, M., Kool-Houweling, L., Strongman, H., Linder, M., Dolin, P., et al. (2016) · BMJ · doi:10.1136/bmj.i3903 · Cited by 71
Chigurupati, S., Dhanaraj, S. A., & Balakumar, P. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.02.043 · Cited by 70
The 2012 SEMDSA Guideline for the Management of Type 2 Diabetes (Revised)
(2012) · Journal of Endocrinology Metabolism and Diabetes of South Africa · doi:10.1080/22201009.2012.10872287 · Cited by 69
Zhu, Z., Shen, Z., Lu, Y., Zhong, S., & Chen, X. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.05.006 · Cited by 68
Optimal therapy of type 2 diabetes: a controversial challenge
Dardano, A., Penno, G., Prato, S. D., & Miccoli, R. (2014) · Aging · doi:10.18632/aging.100646 · Cited by 68
Observational follow‐up of the PROactive study: a 6‐year update
Erdmann, E., Song, E., Spanheimer, R., van Troostenburg de Bruyn, A. ‐., & Perez, A. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12180 · Cited by 65
RSSDI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2022
(2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01129-5 · Cited by 65
Data-driven prediction of adverse drug reactions induced by drug-drug interactions
Liu, R., AbdulHameed, M. D. M., Kumar, K., Yu, X., Wallqvist, A., & Reifman, J. (2017) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-017-0153-6 · Cited by 65
Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies.
Brunetti, L., & Kalabalik, J. (2012) · PubMed · Cited by 63
Heterocyclic compounds as a magic bullet for diabetes mellitus: a review
Farwa, U., & Raza, M. A. (2022) · RSC Advances · doi:10.1039/d2ra02697j · Cited by 62
Ptaszynska, A., Cohen, S. M., Messing, E. M., Reilly, T. P., JOHNSSON, E. K., & Johnsson, K. M. (2015) · Diabetes Therapy · doi:10.1007/s13300-015-0128-9 · Cited by 62
Cefalu, W. T., Buse, J. B., Del Prato, S., Home, P. D., LeRoith, D., Nauck, M. A., Raz, I., Rosenstock, J., & Riddle, M. C. (2014) · Diabetes Care · doi:10.2337/dc14-1395 · Cited by 61
Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: Clinical Implications and Treatment
Rahimi, R. S., & Landaverde, C. (2013) · Nutrition in Clinical Practice · doi:10.1177/0884533612470464 · Cited by 61
Glycogen phosphorylase inhibitors: a patent review (2013 - 2015)
Donnier‐Maréchal, M., & Vidal, S. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2016.1131268 · Cited by 61
Genuth, S. (2015) · Diabetes Care · doi:10.2337/dc14-0565 · Cited by 60
Pioglitazone inhibits the proliferation and metastasis of human pancreatic cancer cells
Ninomiya, I., Yamazaki, K., Oyama, K., Hayashi, H., Tajima, H., Kitagawa, H., Fushida, S., Fujimura, T., & Ohta, T. (2014) · Oncology Letters · doi:10.3892/ol.2014.2553 · Cited by 59
Glucocorticoid receptor beta increases migration of human bladder cancer cells
McBeth, L., Nwaneri, A. C., Grabnar, M., Demeter, J., Nestor‐Kalinoski, A. L., & Hinds, T. D. (2016) · Oncotarget · doi:10.18632/oncotarget.8430 · Cited by 59
Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease.
Shah, J., Okubote, T. C., & Alkhouri, N. (2018) · Europe PMC (PubMed Central) · Cited by 58
Jin, S., Park, C. ‐., Cho, Y. M., Ku, B. J., Ahn, C. W., Cha, B. ‐., Min, K. W., Sung, Y., Baik, S. H., Lee, K. W., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12435 · Cited by 57
Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes
Tseng, C. (2014) · Acta Diabetologica · doi:10.1007/s00592-014-0562-6 · Cited by 57
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 57
Kůs, V., Flachs, P., Kuda, O., Bardová, K., Janovská, P., Svobodová, M., Jílková, Z. M., Rossmeisl, M., Wang‐Sattler, R., Yu, Z., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027126 · Cited by 56
Smith, R. C., Jin, H., Li, C., Bark, N. M., Shekhar, A., Dwivedi, S., Mortiere, C., Lohr, J. B., Hu, Q., & Davis, J. M. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.10.023 · Cited by 56
Use of the Analytic Hierarchy Process for Medication Decision-Making in Type 2 Diabetes
Maruthur, N. M., Joy, S. M., Dolan, J. G., Shihab, H. M., & Singh, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126625 · Cited by 55
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 54
Diabetes and Cancer: 5 Years Into the Recent Controversy
Badrick, E., & Renehan, A. G. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.032 · Cited by 53
Vallarino, C., Perez, A., Fusco, G., Liang, H., Bron, M., Manne, S., Joseph, G., & Yu, S. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0106-9 · Cited by 53
Peroxisome Proliferator-Activated Receptor Agonists and Bladder Cancer: Lessons from Animal Studies
Tseng, C., & Tseng, F.-H. (2012) · Journal of Environmental Science and Health Part C · doi:10.1080/10590501.2012.735519 · Cited by 53
Indole and 2,4-Thiazolidinedione conjugates as potential anticancer modulators
Corigliano, D. M., Syed, R., Messineo, S., Lupia, A., Patel, R. V., Reddy, C. V. R., Dubey, P. K., Colica, C., Amato, R., Sarro, G. D., et al. (2018) · PeerJ · doi:10.7717/peerj.5386 · Cited by 53
Yang, X., Ma, R. C. W., So, W. Y., Kong, A. P. S., Xu, G., & Chan, J. C. N. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01551.x · Cited by 51
Pioglitazone and vitamin E for nonalcoholic steatohepatitis: A cost utility analysis
Mahady, S. E., Wong, G., Craig, J. C., & George, J. (2012) · Hepatology · doi:10.1002/hep.25887 · Cited by 51
Emerging and future therapies for nonalcoholic steatohepatitis in adults
Mintziori, G., & Polyzos, S. A. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1225727 · Cited by 50
He, S., Tang, Y.-H., Zhao, G., Yang, X., Wang, D., & Zhang, Y. (2013) · Tumor Biology · doi:10.1007/s13277-013-1278-x · Cited by 50
Reverse translation of adverse event reports paves the way for de-risking preclinical off-targets
Maciejewski, M., Lounkine, E., Whitebread, S., Farmer, P. J., DuMouchel, W., Shoichet, B. K., & Urbán, L. (2017) · eLife · doi:10.7554/elife.25818 · Cited by 50
Tai, Y., Chen, C., Huang, C., Tai, H., Wang, S., & Pu, Y. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2614 · Cited by 50
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Viscoli, C. M., Kernan, W. N., & Young, L. H. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1605904 · Cited by 50
Griggs, R. B., Donahue, R. R., Adkins, B. G., Anderson, K. L., Thibault, O., & Taylor, B. K. (2016) · The Journal of Pain · doi:10.1016/j.jpain.2015.11.006 · Cited by 49
van Raalte, D. H., van Genugten, R. E., Eliasson, B., Möller-Goede, D. L., Mari, A., Tura, A., Wilson, C., Fleck, P. R., Taskinen, M., Smith, U., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0639 · Cited by 49
Pharmacogenetics in type 2 diabetes: influence on response to oral hypoglycemic agents
Pearson, E. R., Dawed, A. Y., & Zhou, K. (2016) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s84854 · Cited by 49
Gao, J., Cheng, Y., Hao, H., Yin, Y., Xue, J., Zhang, Q., Li, L., Liu, J., Xie, Z., Yu, S., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1338-2 · Cited by 49
Sethi, N. S., Prasad, D. N., & Singh, R. K. (2019) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557519666191029102838 · Cited by 49
Home, P. (2013) · Diabetes Care · doi:10.2337/dcs13-2002 · Cited by 49
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 48
The role and function of PPARγ in bladder cancer
Peng, T., Wang, G., Cheng, S., Xiong, Y., Cao, R., Qian, K., Ju, L., Wang, X., & Xiao, Y. (2020) · Journal of Cancer · doi:10.7150/jca.42663 · Cited by 48
Self-citationDu, Q., Yang, S., Wang, Y.-J., Wu, B., Zhao, Y.-Y., & Fan, B. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0044-6 · Cited by 47
Xing, Z., Yang, T., Li, X., Xu, H., Hong, Y., Shao, S., Li, T., Ye, L., Li, Y., Jin, X., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115545 · Cited by 47
Vaccaro, O., Masulli, M., Bonora, E., Prato, S. D., Giorda, C. B., Maggioni, A. P., Mocarelli, P., Nicolucci, A., Rivellese, A. A., Squatrito, S., et al. (2012) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.09.003 · Cited by 47
Zhan, Y., Liu, Y., Wang, C., Lin, J., Chen, M., Chen, X., Zhuang, C., Liu, L., Xu, W., Zhou, Q., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.6946 · Cited by 47
DIGENIO, A. G., Pham, N. C., Watts, L. M., Morgan, E. S., Jung, S. W., Baker, B. F., Geary, R. S., & Bhanot, S. (2018) · Diabetes Care · doi:10.2337/dc17-2132 · Cited by 47
Changing patterns of sexually transmitted infections in India.
Sharma, V., & Khandpur, S. (2004) · PubMed · Cited by 47
Antonucci, N., Cirillo, A., & Siniscalco, D. (2015) · Case Reports in Psychiatry · doi:10.1155/2015/325061 · Cited by 47
Sinha, B., & Ghosal, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-72967-8 · Cited by 46
PPARγ Modulators in Lung Cancer: Molecular Mechanisms, Clinical Prospects, and Challenges
Zhang, J., Tang, M., & Shang, J. (2024) · Biomolecules · doi:10.3390/biom14020190 · Cited by 46
Functional role of peroxisome‐proliferator‐activated receptor γ in hepatocellular carcinoma
Wu, C., Farrell, G. C., & Yu, J. Q. (2012) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2012.07213.x · Cited by 46
Lincoff, A. M., Tardif, J., Neal, B. C., Nicholls, S. J., Rydén, L., Schwartz, G. G., Malmberg, K., Buse, J. B., Henry, R. R., Wedel, H., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.013 · Cited by 46
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 45
Medical and Surgical Treatment Options for Nonalcoholic Steatohepatitis
Corey, K. E., & Rinella, M. E. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4083-8 · Cited by 44
Non-alcoholic Fatty Liver Disease and Diabetes Mellitus
Khneizer, G. W., Rizvi, S., & Gawrieh, S. (2020) · Advances in experimental medicine and biology · doi:10.1007/5584_2020_532 · Cited by 44
Targets to treat metabolic syndrome in polycystic ovary syndrome
Mahalingaiah, S., & Diamanti-Kandarakis, E. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1101067 · Cited by 43
Metadata
- Authors
- Lewis, J. D., Ferrara, A., Peng, T., Hedderson, M., Bilker, W. B., Quesenberry, C. P., Vaughn, D. J., Nessel, L., Selby, J., & Strom, B. L.
- Affiliations
- University of Pennsylvania (US)
- Kaiser Permanente (US)
- Corresponding author
- Lewis, James D.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-03-21
- Volume
- 34
- Issue
- 4
- Pages
- 916-922
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3064051
- OpenAlex
- W2121264929
- Cited by
- 625
- References
- 24
- Citations by year
- 2026: 8 · 2025: 11 · 2024: 10 · 2023: 10 · 2022: 19 · 2021: 18 · 2020: 25 · 2019: 21 · 2018: 29 · 2017: 35 · 2016: 55 · 2015: 58 · 2014: 79 · 2013: 90 · 2012: 119
- FWCI
- 42.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- pioglitazone, bladder cancer, diabetes mellitus, drug safety, cancer risk, treatment duration, thiazolidinediones, antidiabetic drugs, early-stage cancer detection
- MeSH terms
- Pioglitazone, Adult, Aged, Urinary Bladder Neoplasms, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Longitudinal Studies, Male, Middle Aged, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.